Cancer research: past, present and future.

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31

Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Exp Clin Cancer Res (2013) 1.14

Using space-based investigations to inform cancer research on Earth. Nat Rev Cancer (2013) 1.08

Curtailing side effects in chemotherapy: a tale of PKCδ in cisplatin treatment. Oncotarget (2012) 1.04

Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care (2013) 1.00

Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs. Nat Commun (2014) 0.97

Anti-cancer potential of a novel SERM ormeloxifene. Curr Med Chem (2013) 0.89

Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal (2012) 0.88

Curcumin treatment alters ERK-1/2 signaling in vitro and inhibits nasopharyngeal carcinoma proliferation in mouse xenografts. Int J Clin Exp Med (2014) 0.85

Hydrogels to model 3D in vitro microenvironment of tumor vascularization. Adv Drug Deliv Rev (2014) 0.85

Polycyclic aromatic hydrocarbons and childhood asthma. Eur J Epidemiol (2015) 0.83

PFTK1 Promotes Gastric Cancer Progression by Regulating Proliferation, Migration and Invasion. PLoS One (2015) 0.80

Personalized nanomedicine: future medicine for cancer treatment. Int J Nanomedicine (2013) 0.80

DINGO: differential network analysis in genomics. Bioinformatics (2015) 0.79

Prognostic values of four Notch receptor mRNA expression in gastric cancer. Sci Rep (2016) 0.78

Evaluation of cytolytic activity and phenotypic changes of circulating blood immune cells in patients with colorectal cancer by a simple preparation of peripheral blood mononuclear cells. J Korean Surg Soc (2013) 0.75

Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management. Hum Vaccin Immunother (2016) 0.75

Exome sequencing reveals a potential mutational trajectory and treatments for a specific pancreatic cancer patient. Onco Targets Ther (2014) 0.75

miR-18a downregulates DICER1 and promotes proliferation and metastasis of nasopharyngeal carcinoma. Int J Clin Exp Med (2014) 0.75

Expression of sperm-specific protamines impairs bacterial and eukaryotic cell proliferation. Histochem Cell Biol (2015) 0.75

Anticancer metallohelices: nanomolar potency and high selectivity. Chem Sci (2015) 0.75

Upregulation of ROCK2 in gastric cancer cell promotes tumor cell proliferation, metastasis and invasion. Clin Exp Med (2016) 0.75

Hallmarks of cancer: the next generation. Cell (2011) 140.01

Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40

Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67

The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48

Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63

Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44

The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43

Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell (2006) 11.79

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60

Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev (2008) 7.87

Translating cancer research into targeted therapeutics. Nature (2010) 7.33

Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell (2009) 7.09

Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34

Exploring the genomes of cancer cells: progress and promise. Science (2011) 6.16

Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov (2010) 6.07

Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature (1992) 5.50

Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci Am (2007) 4.66

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene (2001) 3.36

Non-oncogene addiction and the stress phenotype of cancer cells. Cell (2007) 3.19

Making sense of cancer genomic data. Genes Dev (2011) 3.01

Mutant BRAF melanomas--dependence and resistance. Cancer Cell (2011) 2.87

Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene (2010) 2.76

Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer (2010) 2.68

Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res (2009) 2.63

Tumor-host interactions: a far-reaching relationship. J Clin Oncol (2010) 2.48

Genomics and the continuum of cancer care. N Engl J Med (2011) 2.26

CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett (2008) 1.75

HPV prophylactic vaccination: The first years and what to expect from now. Cancer Lett (2010) 1.65

Towards patient-based cancer therapeutics. Nat Biotechnol (2010) 1.63

World Health Organization cancer priorities in developing countries. Ann Oncol (2006) 1.44

Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res (2011) 1.40

Inhibition of protein-protein interactions using designed molecules. Chem Soc Rev (2009) 1.40

Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum (1995) 1.38

Searching for synthetic lethality in cancer. Curr Opin Genet Dev (2011) 1.34

Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine. Curr Opin Pharmacol (2008) 1.09

From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin Pharmacol Ther (2009) 1.06

EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. Front Biosci (Landmark Ed) (2011) 0.97

International network of cancer genome projects. Nature (2010) 20.35

Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20

FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33

The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21

Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05

Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature (2006) 9.20

FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94

Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27

Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16

Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol (2006) 7.89

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81

The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77

Pancreatic cancer biology and genetics. Nat Rev Cancer (2002) 7.36

Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36

HDAC2 negatively regulates memory formation and synaptic plasticity. Nature (2009) 6.96

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53

Telomere dysfunction induces metabolic and mitochondrial compromise. Nature (2011) 6.36

gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell (2009) 6.26

Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature (2002) 6.10

Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol (2007) 5.99

How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol (2007) 5.80

Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65

Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53

Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11

Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell (2010) 5.08

Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev (2004) 5.00

p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00

Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80

Connecting chromosomes, crisis, and cancer. Science (2002) 4.69

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57

PI3 kinase signals BCR-dependent mature B cell survival. Cell (2009) 4.43

Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science (2003) 4.32

Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat Immunol (2009) 4.31

Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med (2002) 4.28

Telomeres and telomerase in cancer. Carcinogenesis (2009) 4.28

Correlation of structural elements and infectivity of the HET-s prion. Nature (2005) 4.01

The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76

High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A (2004) 3.75

SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69

Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest (2005) 3.66

IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell (2011) 3.61

FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. Cell Stem Cell (2009) 3.37

Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell (2009) 3.37

Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab (2008) 3.22

CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med (2006) 3.11

Passenger deletions generate therapeutic vulnerabilities in cancer. Nature (2012) 3.11

Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell (2002) 3.06

Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat Immunol (2010) 3.05

STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology (2006) 3.05

Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature (2003) 2.92

Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev (2004) 2.91

Stromal biology of pancreatic cancer. J Cell Biochem (2007) 2.88

Telomeres, stem cells, senescence, and cancer. J Clin Invest (2004) 2.87

Essential role of limiting telomeres in the pathogenesis of Werner syndrome. Nat Genet (2004) 2.83

AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell (2011) 2.77

STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. Immunity (2002) 2.77

Generation of functional insulin-producing cells in the gut by Foxo1 ablation. Nat Genet (2012) 2.75

PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell (2010) 2.68

Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med (2002) 2.58

A Foxo/Notch pathway controls myogenic differentiation and fiber type specification. J Clin Invest (2007) 2.57

Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat Genet (2002) 2.53

Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol (2008) 2.50

mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc Natl Acad Sci U S A (2008) 2.48

FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. J Clin Invest (2009) 2.46

Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev (2003) 2.38

PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell (2013) 2.38

Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nat Immunol (2009) 2.32

A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med (2008) 2.31

SLP-65 regulates immunoglobulin light chain gene recombination through the PI(3)K-PKB-Foxo pathway. Nat Immunol (2008) 2.29

LKB1 (XEEK1) regulates Wnt signalling in vertebrate development. Nat Cell Biol (2003) 2.24

Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells. J Exp Med (2010) 2.17

The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis. Oncogene (2004) 2.14

PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov (2011) 2.14

STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis. Gastroenterology (2006) 2.13

p53: good cop/bad cop. Cell (2002) 2.11

p16(Ink4a) in melanocyte senescence and differentiation. J Natl Cancer Inst (2002) 2.09

Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice. Endocrinology (2011) 2.07

Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med (2005) 2.06

Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc Natl Acad Sci U S A (2002) 2.03

FoxO transcription factors promote cardiomyocyte survival upon induction of oxidative stress. J Biol Chem (2010) 2.00

Telomere shortening exposes functions for the mouse Werner and Bloom syndrome genes. Mol Cell Biol (2004) 1.99

Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell (2011) 1.99

SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities. J Biol Chem (2002) 1.99

Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A (2008) 1.92

Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell (2012) 1.91

Cancer: crime and punishment. Nature (2005) 1.91

General nature of the STAT3-activated anti-inflammatory response. J Immunol (2006) 1.90

Elevated telomere-telomere recombination in WRN-deficient, telomere dysfunctional cells promotes escape from senescence and engagement of the ALT pathway. Genes Dev (2005) 1.84

Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Gastroenterology (2004) 1.79

Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol Cell Biol (2005) 1.78

Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation (2010) 1.76

Molecular diversity of astrocytes with implications for neurological disorders. Proc Natl Acad Sci U S A (2004) 1.76

Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell (2012) 1.75

Axis of ageing: telomeres, p53 and mitochondria. Nat Rev Mol Cell Biol (2012) 1.74

From the Cover: Neutralization of terminal differentiation in gliomagenesis. Proc Natl Acad Sci U S A (2013) 1.71

Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling? Cell Div (2010) 1.70

IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol (2008) 1.69